MAR 31, 2019 8:34 PM PDT

Glowing Tumors Reveal How Immunotherapeutics Work

WRITTEN BY: Nouran Amin

In a study published in the Journal of Clinical Investigation, researchers used positron emission tomography (PET) scans to examine how an immunotherapy drug reaches a tumor and the parts of a cancer that remain unaffected.

Learn more about how PET scans work:

The process of PET imaging uses a synthesized radiolabeled protein that locks on to tumor cells—this allows researchers to visually follow where the so-called checkpoint inhibitor drug binds to a tumor. "This approach offers a vital step toward directly measuring how well immunotherapy drugs are able to engage a tumor in any given person," says Sridhar Nimmagadda, Ph.D., associate professor of radiology and radiological science at the Johns Hopkins University School of Medicine and a member of the Sidney Kimmel Comprehensive Cancer Center.

Radiolabeled protein lights up tumor implanted in the arm of a mouse under a PET scan. The researchers hope to use scans like this one to calculate in real time how much of an immunotherapy drug reaches a tumor and what parts of a cancer remain unaffected. Credit: Sridhar Nimmagadda via John Hopkins

If PET imaging precision is confirmed to be highly effective in additional tests, it could streamline cancer therapy by enhancing the therapeutic dose of a drug. The use of checkpoint inhibitors is a form of cancer therapy designed to help the immune systems recognize cancer cells and to target them. For example, the programmed death ligand 1 (PD-L1) is one such checkpoint target by three approved therapeutics called atezolizumab, avelumab and durvalumab by the U.S. Food and Drug Administration (FDA).

In the study, researchers created a radiolabeled small protein that binds to PD-L1 which facilitates marking its receptor with a radiotracer seen with PET imaging technique. "In human patients, this could give us some insight about how to optimize further treatments by increasing the dose or substituting other drugs or therapies more quickly,” says Nimmagadda.

Source: John Hopkins School of Medicine

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
NOV 04, 2021
Drug Discovery & Development
The first FDA approved eye drops to treat presbyopia and correct poor near-vision.
NOV 04, 2021
The first FDA approved eye drops to treat presbyopia and correct poor near-vision.
Your Grandma's favorite eyeglasses may soon find their way to the trashcan. Last Friday, October 29th, the United States ...
NOV 10, 2021
Drug Discovery & Development
Inflammation during pregnancy can affect normal brain development
NOV 10, 2021
Inflammation during pregnancy can affect normal brain development
During pregnancy the growing embryo and fetus undergo remarkable and quick developmental. Around 5 weeks after ...
NOV 25, 2021
Immunology
Battling Bacterial Pneumonia, No Antibiotics Required
NOV 25, 2021
Battling Bacterial Pneumonia, No Antibiotics Required
Instead of flooding the body with antibiotics, what if we could program cells to fight off pathogens more effectively? T ...
NOV 23, 2021
Health & Medicine
No Short Term Effects of THC-positive Breast Milk
NOV 23, 2021
No Short Term Effects of THC-positive Breast Milk
A recent study found that THC does not have short-term negative effects on an early, premature baby’s health. Rese ...
JAN 14, 2022
Clinical & Molecular DX
No, It's Not Just Insulin That Regulates Blood Sugar
JAN 14, 2022
No, It's Not Just Insulin That Regulates Blood Sugar
  In a research breakthrough, scientists have found a hormone secreted by fat cells that plays a similar role to in ...
JAN 10, 2022
Cancer
Race May Impact Radiation Efficacy in Prostate Cancer Patients
JAN 10, 2022
Race May Impact Radiation Efficacy in Prostate Cancer Patients
Racial disparities exist between Black and White populations in many types of cancer.  Researchers actively investi ...
Loading Comments...